On balance, the price targets are lower but the majority of the analysts have maintained buy ratings and the stock has shown impressive price stability in the face of lowered earnings and revenue projections. Clearly the long term view is positive for VRTX in the eyes of most investors, and the dip yesterday seems to be taken as a buying opportunity.
The news flow for the remainder of the year will be hep C clinical trial results and initiation of phase 2 trials using the Alios nucs. Also coming influenza Phase 2 trial results, if positive, may raise higher price targets by analysts who have not yet factored in it's potential. The initiation of additional Phase 2 trials using VX 509 in other diseases besides RA later this year will be another catalyst. Any improvement in Incivek sales would also be a plus if prior SOC treatment failures and HIV hep C coinfected patients are seeking treatament over the next year in increasing numbers because of the risks of dying from their illness. Waiting years for IFN free treatment regimens of uncertain efficacy may be a lethal gamble for these paitients, and Vertex marketing team needs to emphasize and promote the proven success rates of it's treatment in these difficult to treat subgroups who have the greatest near term risk of death from their disease.